Holen Sie sich die Stockscreener-App
10.00
2.34%
0.15
Schlusskurs vom Vortag:
$9.85
Offen:
$9.79
24-Stunden-Volumen:
11,044
Relative Volume:
0.01
Marktkapitalisierung:
$63.15M
Einnahmen:
$71,000
Nettoeinkommen (Verlust:
$-2.47M
KGV:
-0.3038
EPS:
-32.9143
Netto-Cashflow:
$-5.24M
1W Leistung:
+2.86%
1M Leistung:
-3.26%
6M Leistung:
-25.28%
1J Leistung:
-43.53%
1-Tages-Spanne:
$9.79
$10.15
1-Wochen-Bereich:
$9.41
$10.24
52-Wochen-Spanne:
$6.00
$28.44
Pavmed Inc Stock (PAVM) Company Profile
Firmenname
Pavmed Inc
Sektor
Branche
Telefon
(212) 949-4319
Adresse
360 MADISON AVENUE, NEW YORK, NY
Compare PAVM vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PAVM
Pavmed Inc
|
10.00 | 62.21M | 71,000 | -2.47M | -5.24M | -32.91 |
ABT
Abbott Laboratories
|
102.15 | 178.75B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.01 | 126.97B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.25 | 111.22B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.58 | 93.36B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.73B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pavmed Inc Stock (PAVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-05 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2018-06-28 | Eingeleitet | Maxim Group | Buy |
Pavmed Inc Aktie (PAVM) Neueste Nachrichten
Q3 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
Big Money Moves: Whats next for PAVmed Inc stockBuy Signal & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PAVM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
PAVmed (PAVM) CEO Lishan Aklog awarded 350,000 restricted shares vesting 2029 - Stock Titan
Craig Kallman (PAVM) holds 384,616 shares, a 6.0% stake in PAVmed - Stock Titan
PAVmed (PAVM) CFO awarded 180,000 restricted shares vesting 2029 - Stock Titan
Director at PAVmed (PAVM) receives 13,930 restricted stock shares - Stock Titan
PAVmed (PAVM) director Timothy Baxter receives 13,930 restricted shares vesting in 2029 - Stock Titan
Restricted stock grant boosts PAVmed (PAVM) director’s holdings - Stock Titan
PAVmed (PAVM) director gets 13,930-share restricted stock grant - Stock Titan
Restricted stock award boosts PAVmed (NASDAQ: PAVM) director stake - Stock Titan
Tasso Partners and Dana Carrera disclose 14.3% stake in PAVmed (PAVM) - Stock Titan
PAVmed (PAVM) general counsel receives 110,000-share restricted award - Stock Titan
PAVmed (PAVM) COO receives 110,000-share restricted stock grant vesting 2029 - Stock Titan
Lucid Diagnostics Inc. (LUCD) stock price, news, quote and history - Yahoo Finance UK
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio - Bitget
PAVmed appoints Joseph Virgilio as medical device chief By Investing.com - Investing.com Australia
PAVmed raises $45 million, restructures capital to eliminate convertible debt - Investing.com
PAVmed: Octeris, Inc. Subsidiary Formed to Advance Endoscopic Esophageal Imaging Tech Recently Licensed From Duke University >PAVM - Moomoo
PAVmed appoints Joseph Virgilio as medical device chief - Investing.com
PAVM Technical Analysis | Trend, Signals & Chart Patterns | PAVMED INC (NASDAQ:PAVM) - ChartMill
PAVmed Inc. (NASDAQ:PAVM) Q4 2025 Earnings Call Transcript - Insider Monkey
PAVmed raises $45 million, restructures capital to eliminate convertible debt By Investing.com - Investing.com India
Maxim Group Maintains PAVmed(PAVM.US) With Buy Rating, Cuts Target Price to $16 - Moomoo
PAVmed Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Fundamentals Check: Is PAVmed Inc a potential multi baggerWeekly Profit Recap & High Conviction Buy Zone Picks - baoquankhu1.vn
PAVmed completes $45M financing, eliminates convertible debt By Investing.com - Investing.com Australia
PAVmed (PAVM) upgraded to buy: Here's what you should know - MSN
PAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Re - GuruFocus
PAVmed Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:PAVM) 2026-03-30 - Seeking Alpha
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
PAVM: Q4 2025 featured diagnostic revenue growth, a VA contract, and improved non-GAAP loss per share - TradingView
PAVmed Reports 2025 Financial Results, Strengthens Capital Structure, and Expands Medical Device Portfolio Under New Leadership - Minichart
Earnings call transcript: PAVmed Q4 2025 shows restructuring gains By Investing.com - Investing.com India
Earnings call transcript: PAVmed Q4 2025 shows restructuring gains - Investing.com
PAVM: Restructuring and growth initiatives drive commercial momentum and financial stability - TradingView
PAVmed Reports Q4 2025 Financial Results with Key Metrics - Intellectia AI
PAVmed Reports 2025 Results, Strengthens Balance Sheet - TipRanks
Q4 2025 PAVmed Inc Earnings Call Transcript - GuruFocus
PAVmed completes $45M financing, eliminates convertible debt - Investing.com
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
PAVmed (NASDAQ: PAVM) overhauls capital structure and reports 2025 results - Stock Titan
PAVM: Q4 2025 featured capital restructuring, expanded diagnostics, and improved financials - TradingView
PAVmed Q4 2025 Earnings Call Transcript - MarketBeat
PAVmed to Announce Q4 Earnings on March 30 - Intellectia AI
PAVmed Q2 2025 Earnings Preview - MSN
PAVmed Inc. 8-K Filing Details: Company Information, Nasdaq Listing, and 2026 Shareholder Meeting Results - Minichart
PAVmed Inc. 2025 Annual Report: Financials, Risk Factors, and Corporate Governance Overview - Minichart
Bear Alert: Whats next for PAVmed Inc stock2026 Sector Moves & Safe Capital Growth Tips - baoquankhu1.vn
PAVmed's Capital Cleanup Hides High-Reward Catalyst for Patient Biotech Investors - Bitget
PAVmed Shareholders Approve Equity Issuance and Governance Changes - TipRanks
Finanzdaten der Pavmed Inc-Aktie (PAVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.25%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):